BiotechTube

efatutazone + paclitaxel

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Thyroid Cancer

Conditions

Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer

Trial Timeline

Dec 30, 2014 → Apr 15, 2023

NCT ID
NCT02152137

About efatutazone + paclitaxel

efatutazone + paclitaxel is a phase 2 stage product being developed by Daiichi Sankyo for Anaplastic Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02152137. Target conditions include Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic Thyroid Cancer were approved

Approved (0) Terminated (0) Active (1)
🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02152137Phase 2Completed

Competing Products

20 competing products in Anaplastic Thyroid Cancer

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
Lenvatinib 24 mgEisaiPhase 2
27
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
LDK378 + AUY922NovartisPhase 1
29
ceritinibNovartisPre-clinical
30
LDK378NovartisPhase 1
29
CeritinibNovartisPhase 2
27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
29
dabrafenib/trametinibNovartisPhase 2
42
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
44
Sunitinib MalatePfizerPhase 2
35
Crizotinib (PF-02341066)PfizerPhase 2
35
LorlatinibPfizerPhase 2
31
CrizotinibPfizerPhase 1/2
32
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
36
Etirinotecan pegolNektar TherapeuticsPhase 2
29
BevacizumabNovocurePhase 2
36